The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System

7 páginas

Autores:: Ariza Lozano, Juan Guillermo
Thuresson MPharm, Per-Olof
Machnicki, Gerardo
Mungapen, Laura
Kraemer, Matthias
Asukai, Yumi
Giraldo Cadavid, Luis Fernando

Tipo de recurso:

Fecha de publicación:: 2012

Institución:: Universidad de la Sabana

Repositorio:: Repositorio Universidad de la Sabana

Idioma:: eng

id	REPOUSABA2_c1f07069f6ee971eaa3018fe0d4ef30d
oai_identifier_str	oai:intellectum.unisabana.edu.co:10818/36812
network_acronym_str	REPOUSABA2
network_name_str	Repositorio Universidad de la Sabana
repository_id_str
spelling	Ariza Lozano, Juan GuillermoThuresson MPharm, Per-OlofMachnicki, GerardoMungapen, LauraKraemer, MatthiasAsukai, YumiGiraldo Cadavid, Luis Fernando8/23/2019 11:282019-08-23T16:28:30Z2012-12https://www.sciencedirect.com/science/article/pii/S2212109912000568#!http://hdl.handle.net/10818/3681210.1016/j.vhri.2012.09.0037 páginasObjectives The main objectives were to estimate the cost-effectiveness and budget impact of indacaterol (a once-daily, long-acting-beta2-agonist) compared with 1) salmeterol/fluticasone, 2) formoterol/budesonide, and 3) tiotropium for the treatment of chronic obstructive pulmonary disease in Colombia. Methods A Markov model was utilized to simulate the progressive course of chronic obstructive pulmonary disease, distinguished by forced expiratory volume in 1 second predicted according to the four Global Initiative for Chronic Obstructive Lung Disease severity stages by using prebronchodilation values. Efficacy was based on the initial improvement in forced expiratory volume in 1 second, taken from either a network meta-analysis (salmeterol/fluticasone and formoterol/budesonide) or a randomized controlled trial (tiotropium). Colombian direct costs and life tables were incorporated in the adaptation, and analysis was performed from a health care payer perspective, discounting future costs (presented as US dollars) and benefits at 5%. A budget impact model was built to estimate the cost impact of indacaterol in Colombia over 3 and 5 years. Results Indacaterol was found to be dominant (i.e., less costly and more effective) against both salmeterol/fluticasone and formoterol/budesonide per life year and quality-adjusted life-year gained after a 5-year time horizon. The average cost saving against salmeterol/fluticasone and formoterol/budesonide was US $411 and US $909 per patient, respectively. All probabilistic sensitivity analysis simulations indicated indacaterol to be less costly than salmeterol/fluticasone and formoterol/budesonide. Indacaterol was more effective and more costly than tiotropium, corresponding to an incremental cost-utility ratio of US $2584 per quality-adjusted life-year.application/pdfengValue in Health RegionalValue in Health Regional Issues Volume 1, Issue 2, December 2012, Pages 165-171Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/http://purl.org/coar/access_right/c_abf2Universidad de La SabanaIntellectum Repositorio Universidad de La SabanaCOPDCost-effectivenessIndacaterolColombiaThe Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health SystemThe Cost Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health SystemarticlepublishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://intellectum.unisabana.edu.co/bitstream/10818/36812/2/license_rdf4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8498https://intellectum.unisabana.edu.co/bitstream/10818/36812/3/license.txtf52a2cfd4df262e08e9b300d62c85cabMD5310818/36812oai:intellectum.unisabana.edu.co:10818/368122022-05-10 05:18:03.493Intellectum Universidad de la Sabanacontactointellectum@unisabana.edu.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
dc.title.es_CO.fl_str_mv	The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System
dc.title.alternative.en.fl_str_mv	The Cost Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System
title	The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System
spellingShingle	The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System COPD Cost-effectiveness Indacaterol Colombia
title_short	The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System
title_full	The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System
title_fullStr	The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System
title_full_unstemmed	The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System
title_sort	The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System
dc.creator.fl_str_mv	Ariza Lozano, Juan Guillermo Thuresson MPharm, Per-Olof Machnicki, Gerardo Mungapen, Laura Kraemer, Matthias Asukai, Yumi Giraldo Cadavid, Luis Fernando
dc.contributor.author.none.fl_str_mv	Ariza Lozano, Juan Guillermo Thuresson MPharm, Per-Olof Machnicki, Gerardo Mungapen, Laura Kraemer, Matthias Asukai, Yumi Giraldo Cadavid, Luis Fernando
dc.subject.es_CO.fl_str_mv	COPD Cost-effectiveness Indacaterol Colombia
topic	COPD Cost-effectiveness Indacaterol Colombia
description	7 páginas
publishDate	2012
dc.date.issued.none.fl_str_mv	2012-12
dc.date.available.none.fl_str_mv	2019-08-23T16:28:30Z
dc.date.accessioned.none.fl_str_mv	8/23/2019 11:28
dc.type.en.fl_str_mv	article
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.hasVersion.es_CO.fl_str_mv	publishedVersion
dc.identifier.other.none.fl_str_mv	https://www.sciencedirect.com/science/article/pii/S2212109912000568#!
dc.identifier.uri.none.fl_str_mv	http://hdl.handle.net/10818/36812
dc.identifier.doi.none.fl_str_mv	10.1016/j.vhri.2012.09.003
url	https://www.sciencedirect.com/science/article/pii/S2212109912000568#! http://hdl.handle.net/10818/36812
identifier_str_mv	10.1016/j.vhri.2012.09.003
dc.language.iso.es_CO.fl_str_mv	eng
language	eng
dc.relation.ispartofseries.none.fl_str_mv	Value in Health Regional Issues Volume 1, Issue 2, December 2012, Pages 165-171
dc.rights.*.fl_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.uri.*.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/4.0/
rights_invalid_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2
dc.format.es_CO.fl_str_mv	application/pdf
dc.publisher.es_CO.fl_str_mv	Value in Health Regional
dc.source.es_CO.fl_str_mv	Universidad de La Sabana Intellectum Repositorio Universidad de La Sabana
institution	Universidad de la Sabana
bitstream.url.fl_str_mv	https://intellectum.unisabana.edu.co/bitstream/10818/36812/2/license_rdf https://intellectum.unisabana.edu.co/bitstream/10818/36812/3/license.txt
bitstream.checksum.fl_str_mv	4460e5956bc1d1639be9ae6146a50347 f52a2cfd4df262e08e9b300d62c85cab
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5
repository.name.fl_str_mv	Intellectum Universidad de la Sabana
repository.mail.fl_str_mv	contactointellectum@unisabana.edu.co
_version_	1766695370005413888

The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System

Publicaciones similares